The technology described in the patent involves a device which is a resorbable and biodegradable structure that can be permeable to oxygen but hermetic to fluids. Also claimed in the patent is the device having outer biodegradable membrane that encompasses nutrients and/or growth factors.
“This new patent broadens our portfolio of unique intellectual property which will further advance our position in human dermal fibroblast regeneration of tissue. Our current portfolio includes 12 U.S. and foreign patents issued and directly owned by the company, along with 38 patents pending,” said Pete O’Heeron, CEO of SpinalCyte.
Based in Houston, Texas, SpinalCyte is a tissue engineering technology company founded to develop a solution for spinal nucleus replacement using human dermal fibroblasts. To date, SpinalCyte has been funded entirely by angel investors.